Trial group of 62 patients and no parasite screening in those patients - yawn. But could be interesting grounds for a more significant and controlled study with patients with comorbidities.
Here's Cochran's meta-study; Cochran is, from what I can tell, very well-regarded. It appears to include this study. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD...
Later
For what it's worth: the boy rebuts this with the observation that you'd expect worsening symptoms for patients with actual parasitic infection, since there's an immune response to necrotic parasite tissue when ivermectin works. None of us here are ivermexperts though!
Separately, I'm having trouble parsing your comment, but I'm curious so I will ask: when you say "the boy rebuts", who is the boy here, yourself? Or..? Maybe I'm just not familiar with this turn of phrase.
But concerning controversy surrounding ivermectin I found this interesting text:
An important controversial point to consider in any rationale is the 5 µM required concentration to reach the anti-SARS-CoV-2 action of ivermectin observed in vitro,17 which is much higher than 0.28 µM, the maximum reported plasma concentration achieved in vivo with a dose of approximately 1700 µg/kg (about nine times the FDA-approved dosification).24 25 In this sense, basic fundamentals for assessing ivermectin in COVID-19 at a clinical level appear to be insufficient. Among other reasons, we believe this might have led WHO to exclude ivermectin from its Solidarity Trial for repurposed drugs for COVID-19,12 which raises questions about the pertinence of conducting clinical studies on ivermectin.
from BMJ, "Misleading clinical evidence and systematic reviews on ivermectin for COVID-19" -- https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111...